IP Library Patent Application 18393293
Patent Application
App. No. 18/393,293

Px-cholorogenic Acid Comps

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/393,293
Abstract

The disclosed compositions, systems and methods relate to compositions for human consumption and comprise a combination of paraxanthine and/or 1-methylxanthine and chlorogenic acid and optionally other compounds that modulate the effects of a combination of paraxanthine and/1-methylxanthine and chlorogenic acid. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of cognitive performance, mood, and/or sleep.

Claims (20)

1 . A composition comprising: about 50 mg to about 400 mg of paraxanthine or 1-methylxanthine and at least about 25 mg chlorogenic acid.

2 . The composition of claim 1 , wherein chlorogenic acid is present in the composition in an amount from about 25 mg to about 500 mg.

3 . The composition of claim 1 , the composition comprises paraxanthine in an amount from about 200 mg to about 400 mg.

4 . The composition of claim 1 , the composition comprises 1-methylxantine in an amount from about 200 mg to about 400 mg.

5 . A method for improving cognitive performance in a subject comprising administering a composition comprising: about 50 mg to about 400 mg of paraxanthine or 1-methylxanthine and at least about 25 mg chlorogenic acid.

6 . The method of claim 5 , wherein chlorogenic acid is present in the composition in an amount from about 25 mg to about 500 mg.

7 . The method of claim 5 , wherein the composition comprises paraxanthine in an amount from about 200 mg to about 400 mg.

8 . The method of claim 7 , wherein the administration of paraxanthine and chlorogenic acid produce a synergistic enhancement of cognitive function in the subject, relative to the administration of paraxanthine or chlorogenic acid alone.

9 . The method of claim 5 , wherein the composition comprises 1-methylxantine in an amount from about 200 mg to about 400 mg.

10 . The method of claim 9 , wherein the administration of 1-methylxanthine and chlorogenic acid produce a synergistic enhancement of cognitive function in the subject, relative to the administration of 1-methylxanthine or chlorogenic acid alone.

11 . The method of claim 5 , wherein improved cognitive performance is measured by an increase in one or more of: attention, information acquisition, information processing, working memory, short-term memory, long-term memory, anterograde memory, retrograde memory, memory retrieval, discrimination learning, decision-making, inhibitory response control, attentional set-shifting, delayed reinforcement learning, reversal learning, the temporal integration of voluntary behavior, speed of processing, reasoning, problem solving and/or social cognition.

12 . The method of claim 11 , wherein improved cognitive performance is measured by improved working memory.

13 . The method of claim 5 , wherein administration of the composition to the subject enhances BDNF expression, glutathione levels, and/or dopaminergic tone, serotonergic tone, cholinergic tone, and/or reduces stress induced cortisol levels.

14 . A method for improving sleep in a subject, comprising administering a composition comprising: about 50 mg to about 400 mg of paraxanthine or 1-methylxanthine and at least about 25 mg chlorogenic acid.

15 . The method of claim 14 , wherein chlorogenic acid is present in the composition in an amount from about 25 mg to about 500 mg.

16 . The method of claim 114 , wherein the composition comprises paraxanthine in an amount from about 200 mg to about 400 mg.

17 . The method of claim 16 , wherein the administration of paraxanthine and chlorogenic acid produce a synergistic improvement of sleep in the subject, relative to the administration of paraxanthine or chlorogenic acid alone.

18 . The method of claim 14 , wherein the composition comprises 1-methylxantine in an amount from about 200 mg to about 400 mg.

19 . The method of claim 18 , wherein the administration of 1-methylxanthine and chlorogenic acid produce a synergistic improvement of sleep in the subject, relative to the administration of 1-methylxanthine or chlorogenic acid alone.

20 . The method of claim 14 , wherein the subject suffers from insomnia.